

January 1, 2012

TO: ALL SWOG MEMBER, CCOP AND AFFILIATE MEDICAL ONCOLOGISTS

AND PATHOLOGISTS

GROUP CHAIR'S OFFICE

FROM: **SWOG Operations Office** 

Laurence H. Baker, DO CHAIR

RE: Repository Relocation Efforts

24 Frank Lloyd Wright Dr PO Box 483

Ann Arbor, MI 48106

734-998-7130 734-998-7118 FAX

## OPERATIONS OFFICE

4201 Medical Dr Suite 250 San Antonio, TX 78229

210-614-8808 210-614-0006 FAX

## STATISTICAL CENTER

1730 Minor Ave Suite 1900

206-342-1616 FAX

1100 Fairview Ave North M3-C102 PO Box 19024 Seattle, WA 98109

206-667-4623 206-667-4408 FAX

## **MEMORANDUM**

The purpose of this memorandum is to provide updated information on the repository relocation efforts.

Effective January 1, 2012 all repository specimen submissions for Cancer Control studies (including Survivorship, Symptom Control and Quality of Life, Outcomes and Comparative Effectiveness, Molecular Epidemiology and Prevention committees) will be routed to the SWOG Specimen Repository - Solid Tissue, Myeloma and Lymphoma Division at Nationwide Children's Hospital.

Due to time constraints and regulatory requirements, individual protocol revisions to reflect these changes may not be distributed on or before the effective dates, but will be distributed as they are available. During this transition period and starting on January 1, sites are instructed to follow specimen submission instructions as outlined on the appropriate SWOG Specimen Submission webpage (http://swog.org/members/clinicaltrials/specimens/stspecimens.asp).

Any specimens that have been logged into the SWOG SpecTrack system for shipment to the existing repository, but that have not yet been shipped in the tracking system as of 1/1/12 will automatically have the destination laboratory changed in the SWOG Specimen Tracking System to the SWOG Specimen Repository - Solid Tissue, Myeloma and Lymphoma Division at Nationwide Children's Hospital.

Note that this transition specifically affects only specimens submitted to the repository for banking purposes; specimens submitted for protocol specific translational medicine studies or for other purposes outlined in the treatment protocol will continue to be submitted as outlined in the protocol.

The transitions for the hematologic malignancies (leukemia, lymphoma and myeloma) began being routed to the repository at Nationwide effective November 1, 2011 and all repository specimen submissions for solid tumor disease sites began being routed to the repository at Nationwide effective December 1, 2011.

Questions regarding this transition should be directed to the SWOG Operations Office at 210/614-8808.

swog.org

